FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283397477> ?p ?o ?g. }

• W4283397477 endingPage "1549" @default.
• W4283397477 startingPage "1548" @default.
• W4283397477 abstract "Background: The acute leukemias (AL) often present with both pro-haemorrhagic and pro-thrombotic complications, through a variety of different mechanisms. Life-threatening consumptive coagulopathy with hyperfibrinolysis is well described in acute promyelocytic leukemias (APL), but non-promyelocytic myeloid leukemias (AML, most notably of monocytic/monoblastic lineage) and lymphoblastic leukemias (ALL) can also develop coagulopathy, often worsened by underproduction thrombocytopenia. Aims: To characterize the presence of altered coagulation screening tests (CST) in (non-APL) AL at diagnosis. Methods: We reviewed all patients (pts) over 18 years old (yo) who presented to our Center with a diagnosis of AL over a 6.5 year period up to 22.02.2022, and who had synchronous diagnostic smears, flow cytometry and CST including fibrinogenemia (Fib) and D-dimers (DD). Fib under 150 mg/dL was considered low (LowFib); DD over 230 ng/mL were considered increased (HiDD). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were analysed as ratios compared to a control (CTR), and were considered increased (>) when over 120%. Results: We studied 188 pts (52% male); 63.3% had AML, 19.7% ALL, 15.4% APL and 1.6% (3 pts) had a biphenotypic AL and were excluded. Ages ranged from 19.2-95.7 yo (mean: 60.3±17.4); AML patients were on average a decade and a half older (65.6±15.3; 51.8±15.3 in APL; 50.9±18.1 in ALL, p<0.001). Within the cohort, 50.5% had a >PT ratio, 11.3% a >aPTT ratio and in 9.7% both were increased; 9.5% of pts had normal Fib and DD, 76.8% had HiDD with normal Fib, and 13.7% had both LowFib and HiDD. Overall, 92.6% of pts had at least one altered test out of four. The mean PT ratio was 1.35±0.75 (1.36±0.31 in APL, 1.39±0.90 in AML, 1.18±0.27 in ALL, p=NS). The proportion of pts with >PT increased from ALL (21.6%) to AML (51.4%) to APL (65.5%), p<0.001. The mean aPTT ratio was 1.00±0.20 (0.94±0.14 in APL, 1.03±0.23 in AML and 0.96±0.13 in ALL, p=0.03); the proportion of pts with >aPTT was not significantly different. ALL pts were twice as likely to have both normal times (80.6%) than AML (39.8%) or APL (34.5%), p=0.001. Mean Fib was lower in APL (178.6±93.4) than AML or ALL (415±199.5 and 351±154.5, p<0.001), with 42.3% of pts with LowFib (7.5% in AML and 0% in ALL, p<0.001). Although the proportion of pts with HiDD was similar in the 3 groups (95.2%, 86.0% and 94.1% in APL, AML and ALL, p=NS), APL pts were more likely to have DD>500 (95.2%, 66.7% and 70.6%, p=0.04), with mean DDs higher in APL (23510±32664) than AML or ALL (3464±6203 and 4399±7248, p<0.001). Overall, 84.7% of pts (including all ALL pts) with HiDD had normal Fib; APL pts were more likely to have both HiDD and LowFib than AML pts (42.9% and 7.0%, respectively, p<0.001). Summary/Conclusion: We found that altered CST were almost universal in AL at diagnosis, irrespective of promyelocytic lineage, with >90% of pts presenting with at least one altered test, most often a prolonged PT – which was found in over half of pts, with its likelihood increasing from one-fifth of pts with ALL to two-thirds of pts with APL, and with ALL pts twice as likely to have normal coagulation times than AML or APL. In concordance with the characteristic coagulopathy of APL, fibrinogenemia in our cohort was 50% lower in APL than in AML or ALL, with almost half of APL pts (but less than 10% of AML pts and no ALL pts) presenting with levels under 150 mg/dL. APL pts were also more likely to have DD over 500 ng/mL (with a mean value that was over five-fold higher than in AML or ALL)¸ and to have both HiDD and LowFib." @default.
• W4283397477 created "2022-06-25" @default.
• W4283397477 creator A5022805561 @default.
• W4283397477 creator A5035274157 @default.
• W4283397477 creator A5037959058 @default.
• W4283397477 creator A5046062882 @default.
• W4283397477 creator A5057514568 @default.
• W4283397477 creator A5063622181 @default.
• W4283397477 date "2022-06-01" @default.
• W4283397477 modified "2023-10-01" @default.
• W4283397477 title "P1667: ALTERED COAGULATION SCREENING TESTS AT DIAGNOSIS ARE A COMMON FINDING IN ACUTE LEUKEMIAS OF BOTH LYMPHOID AND MYELOID LINEAGES, AND NOT JUST IN ACUTE PROMYELOCYTIC LEUKEMIA" @default.
• W4283397477 doi "https://doi.org/10.1097/01.hs9.0000849524.24741.26" @default.
• W4283397477 hasPublicationYear "2022" @default.
• W4283397477 type Work @default.
• W4283397477 citedByCount "0" @default.
• W4283397477 crossrefType "journal-article" @default.
• W4283397477 hasAuthorship W4283397477A5022805561 @default.
• W4283397477 hasAuthorship W4283397477A5035274157 @default.
• W4283397477 hasAuthorship W4283397477A5037959058 @default.
• W4283397477 hasAuthorship W4283397477A5046062882 @default.
• W4283397477 hasAuthorship W4283397477A5057514568 @default.
• W4283397477 hasAuthorship W4283397477A5063622181 @default.
• W4283397477 hasBestOaLocation W42833974771 @default.
• W4283397477 hasConcept C104317684 @default.
• W4283397477 hasConcept C126322002 @default.
• W4283397477 hasConcept C203014093 @default.
• W4283397477 hasConcept C2776601000 @default.
• W4283397477 hasConcept C2776863199 @default.
• W4283397477 hasConcept C2778261982 @default.
• W4283397477 hasConcept C2778382381 @default.
• W4283397477 hasConcept C2778461978 @default.
• W4283397477 hasConcept C2778729363 @default.
• W4283397477 hasConcept C2779282312 @default.
• W4283397477 hasConcept C2779936836 @default.
• W4283397477 hasConcept C2780434524 @default.
• W4283397477 hasConcept C2781121885 @default.
• W4283397477 hasConcept C2781219028 @default.
• W4283397477 hasConcept C55493867 @default.
• W4283397477 hasConcept C71924100 @default.
• W4283397477 hasConcept C86803240 @default.
• W4283397477 hasConcept C90924648 @default.
• W4283397477 hasConceptScore W4283397477C104317684 @default.
• W4283397477 hasConceptScore W4283397477C126322002 @default.
• W4283397477 hasConceptScore W4283397477C203014093 @default.
• W4283397477 hasConceptScore W4283397477C2776601000 @default.
• W4283397477 hasConceptScore W4283397477C2776863199 @default.
• W4283397477 hasConceptScore W4283397477C2778261982 @default.
• W4283397477 hasConceptScore W4283397477C2778382381 @default.
• W4283397477 hasConceptScore W4283397477C2778461978 @default.
• W4283397477 hasConceptScore W4283397477C2778729363 @default.
• W4283397477 hasConceptScore W4283397477C2779282312 @default.
• W4283397477 hasConceptScore W4283397477C2779936836 @default.
• W4283397477 hasConceptScore W4283397477C2780434524 @default.
• W4283397477 hasConceptScore W4283397477C2781121885 @default.
• W4283397477 hasConceptScore W4283397477C2781219028 @default.
• W4283397477 hasConceptScore W4283397477C55493867 @default.
• W4283397477 hasConceptScore W4283397477C71924100 @default.
• W4283397477 hasConceptScore W4283397477C86803240 @default.
• W4283397477 hasConceptScore W4283397477C90924648 @default.
• W4283397477 hasLocation W42833974771 @default.
• W4283397477 hasLocation W42833974772 @default.
• W4283397477 hasLocation W42833974773 @default.
• W4283397477 hasLocation W42833974774 @default.
• W4283397477 hasOpenAccess W4283397477 @default.
• W4283397477 hasPrimaryLocation W42833974771 @default.
• W4283397477 hasRelatedWork W150856653 @default.
• W4283397477 hasRelatedWork W1974693697 @default.
• W4283397477 hasRelatedWork W2008419088 @default.
• W4283397477 hasRelatedWork W2039768501 @default.
• W4283397477 hasRelatedWork W2079794530 @default.
• W4283397477 hasRelatedWork W2161603182 @default.
• W4283397477 hasRelatedWork W2411609336 @default.
• W4283397477 hasRelatedWork W2804678683 @default.
• W4283397477 hasRelatedWork W2945254680 @default.
• W4283397477 hasRelatedWork W4283397477 @default.
• W4283397477 hasVolume "6" @default.
• W4283397477 isParatext "false" @default.
• W4283397477 isRetracted "false" @default.
• W4283397477 workType "article" @default.